Provided is a method for measuring ADAs appearing in a patient receiving molecular-targeted therapy with a drug or the like in a simpler and more accurate manner.
A method for measuring anti-drug antibodies (ADAs) in an analyte to be measured, the method comprising:
(1) a step of providing a sample comprising an analyte to be measured for ADAs, the step comprising adding a corresponding drug to an analyte to be measured for ADAs to prepare a sample with a drug-ADAs immune complex formed;
(2) a step of contacting the sample prepared in step (1) with a carrier coated with complement Clq, anti-C3d antibody, or anti-Clq antibody;
(3) a step of contacting a labeled or non-labeled antibody to a drug corresponding to the ADAs with the coated carrier prepared in step (2); and
(4) a step of quantifying the drug-ADAs immune complex binding to the complement Clq, anti-C3d antibody, or anti-Clq antibody.